Abstract As gene expression profile (GEP) testing for breast cancer may provide additional prognostic information to guide the use of adjuvant chemotherapy, we examined the association between GEP testing and use of chemotherapy, serious chemotherapy-related adverse effects, and total charges during the 12 months following diagnosis. Medical record review was conducted for women age 30-64 years, with incident, non-metastatic, invasive breast cancer diagnosed 2006-2008 in a large, national health plan. Of 534 patients, 25.8% received GEP testing, 68.2% received chemotherapy, and 10.5% experienced a serious chemotherapy-related adverse effect. GEP testing was most commonly used in women at moderate clinical risk of recurrence (52.0 vs. 25.0% of low-risk women and 5.5% of high-risk). Controlling for the propensity to receive GEP testing, women who had GEP were less likely to receive chemotherapy (propensity adjusted odds ratio, 95% confidence interval 0.62, 0.39-0.99). Use of GEP was associated with more chemotherapy use among women at low risk based on clinical characteristics (OR = 42.19; CI 2.50-711.82), but less use among women with a high risk based on clinical characteristics (OR = 0.12; CI 0.03-0.47). Use of GEP was not associated with chemotherapy for the moderate risk group. There was no significant relationship between GEP use and either serious chemotherapy-associated adverse effects or total charges. While GEP testing was associated with an overall decrease in adjuvant chemotherapy, we did not find differences in serious chemotherapy-associated adverse events or charges during the 12 months following diagnosis.
Introduction
Each year in the US more than 200,000 women are diagnosed with breast cancer, about half with early-stage disease [1] . Guidelines suggest that a majority of women with node-negative, estrogen receptor-positive breast cancer should be offered chemotherapy [2, 3] , but as only a minority will have a recurrence, some patients receive little benefit yet experience substantial short and long-term toxicity [4] . Better identification of the women most likely to benefit from adjuvant chemotherapy would be an important advance in the management of women with nonmetastatic breast cancer. From a societal perspective, the costs of adjuvant chemotherapy for non-metastatic breast cancer are substantial, as the total payment by Medicare for the initial treatment of women with breast cancer exceeded $1 billion in 2002 [5] .
Because of the complexities of deciding on the best course of treatment for an individual woman and because of the substantial societal costs associated with the use of adjuvant chemotherapy, there has been intense interest in using genetic information to improve our assessment of recurrence risk among women with non-metastatic breast cancer. Several studies suggest that the genetic profile of a tumor may promote better classification of recurrence risk beyond traditional tumor characteristics, such as tumor size, axillary lymph node involvement, and histology [6] [7] [8] [9] . Using DNA micro-array or real-time polymerase chain reaction (RT-PCR) technology, it is now possible to describe the expression profile of a series of genes and to link that expression profile with an important clinical event, such as recurrence-free survival or predicted benefit from chemotherapy [10] . OncotypeDX (Genomic Health, Redwood City, CA) the most commonly available commercial gene expression profile (GEP) test in the US, provides prognostic and predictive information for women with hormone-receptor positive invasive breast cancer. Data from the manufacturer suggests rapid dissemination since its introduction in 2004 [11] . The test costs about $4,000 [12] , and economic analyses suggest that GEPguided therapy is either cost-saving or associated with a modest incremental cost-effectiveness ratio (ICER) as compared to traditional risk stratification approaches [7, [13] [14] [15] [16] [17] [18] .
Information about the use of GEP testing in routine clinical practice, its association with adjuvant chemotherapy decisions, and its impact on health outcomes and costs are limited [19, 20] . This information is important as new tests are often used for ''off label'' indications as they disseminate into practice and some groups of people may not have access to new technologies. The studies that led to the validation of this technology do not explain how it is used in routine practice or describe the full range of outcomes that could be impacted by GEP testing [21] . As the use of genomic tests to assess recurrence risk is expanding to other cancers [22] , the example of GEP testing for breast cancer is an important prototype for understanding the use of this family of tests in clinical practice. Our objective was to examine the association of GEP with the use of adjuvant chemotherapy, the occurrence of serious chemotherapyassociated adverse effects, and total charges in a payerbased sample of women with non-metastatic breast cancer. As GEP may help clinicians and patients make more personalized decisions about chemotherapy use, our hypothesis was that use of GEP would be associated with fewer chemotherapy-associated adverse effects and therefore lower charges.
Methods

Population
Using claims and administrative data from a large national health plan (the name of which we cannot provide because of our data use agreement), we identified women ages 30-64 years with incident breast cancer diagnosed between 2006 and 2008 [23, 24] . We did not include women C65 years as Medicare is the primary payer for these women. We included women who were continuously enrolled in the plan from 6 months prior through 12 months following diagnosis. Medical records from each woman's primary medical oncologist and surgeon were abstracted for 534 women with stages I-III, hormonereceptor positive invasive breast cancer. This sample size was pre-determined. These women were considered eligible for GEP testing based on previous validation studies and/or clinical practice guidelines [2, 6, 9, 25] .
Benefit coverage
The health plan had a formal coverage policy for OncotypeDx beginning in January 2007, with the requirement that Genomic Health screen all orders for OncotypeDX to make sure that they fit eligibility criteria [26] . Under this policy, the health plan would not cover OncotypeDX testing if an individual received a low-risk OncotypeDX score yet decided to go ahead and receive adjuvant chemotherapy, as this suggests that the test result was not being used as intended [27] . Before this policy was implemented, women may have had claims for OncotypeDX paid on a case-by-case basis, or they could have paid out-of-pocket. Documentation of OncotypeDX in the medical record was not dependent on source of payment. OncotypeDX was the only GEP test received by women in this sample.
Sources of data
Claims
In addition to identifying the cohort, claims were used to determine age, comorbidity [28] , year of diagnosis, serious chemotherapy-associated adverse effects [23] , and charges submitted during the 12 months following diagnosis to reflect the costs of care. Information about costs reimbursed by the payer was not available.
Medical records
A standard abstraction tool was used to collect detailed clinical information, including cancer stage, tumor size, lymph node involvement, estrogen and progesteronereceptor status, HER2 receptor status, the use and results of any GEP tests, and the use of adjuvant chemotherapy. Medical records were reviewed by trained abstractors contracted through a third party vendor.
Outcomes
The primary outcomes were receipt of adjuvant chemotherapy, the occurrence of a serious chemotherapy-related adverse effect [23] , and charges for medical care-all evaluated during the first 12 months following diagnosis. Patients were considered to have received chemotherapy if there was documentation in their medical record of any of the chemotherapy agents commonly administered for breast cancer (adriamycin, carboplatin, cyclophosphamide, docetaxel, fluorouracil, epirubicin, paclitaxel, and albuminbound paclitaxel). A serious chemotherapy-associated adverse event was defined as any hospitalization or emergency department visit with an associated diagnostic code for one or more condition defined as a serious chemotherapy-associated adverse event in our earlier study (e.g., nausea, diarrhea, neutropenia, and infection) [23] . Total charges, reported in US dollars, were the sum of charges for hospital admissions, outpatient visits, emergency department visits, and prescription drugs submitted to the health plan. We set all charges below 2.5% or above 97.5% of the distribution to the value of those percentiles, reducing the influence of extreme outliers [29] .
Predictors and covariates
The predictor of interest in all analyses was receipt of a GEP test. Women were classified as having a low, moderate, or high risk breast cancer using conventional clinical characteristics based on widely disseminated clinical practice guidelines [2, 3] . Low clinical risk was defined as small, node negative cancers without high-risk features (tumor size B 0.5 cm, or tumor size 0.6-1.0 cm with a well-differentiated grade and negative or indeterminate HER2-status); high clinical risk was defined as a nodepositive cancer or a larger node-negative cancer with high risk features (size C 5.0 cm and HER2-negative or indeterminate, or node-negative with a tumor size [ 1.0 cm and HER2-positive); moderate clinical risk included all other cancers. GEP test results were categorized according to the groups defined by the original validation studies as low (recurrence score \ 18), intermediate (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , and high (31?) risk using the actual recurrence score [9] , or when no score was available, the test interpretation. Patient and disease characteristics identified in the medical records and claims included: age (30-49, 50-64), comorbidity score (0 or 1? chronic conditions), year of breast cancer diagnosis (2006, 2007, 2008) , tumor size (\1 cm, 1-2 cm, 2.1-3 cm, [ 3 cm), grade (well differentiated, moderate/ poorly differentiated), nodal status (no vs. any regional lymph node involvement), estrogen-and progesteronereceptor status (one positive, both positive), and HER2-receptor status (negative/intermediate, positive).
Data analysis
Logistic regression models were used to estimate adjusted odds ratios (OR) and 95% confidence intervals (CI) for the use of adjuvant chemotherapy and the occurrence of serious chemotherapy-associated adverse effects, conditional on GEP test use. Propensity score methods were used to control for confounding by characteristics associated with receipt of a GEP test and the study outcomes, which may be particularly important for a newer test like GEP which is not explicitly recommended [2] . We adopted this approach, rather than conventional adjustment, because outcome prevalence was low in some subgroups of interest, and the number of covariates of interest was relatively large considering the overall sample size in these groups [30] . Each woman's propensity to receive a GEP test was estimated a function of her age at diagnosis, comorbidity score, year of breast cancer diagnosis, tumor size, grade, nodal status, hormone receptor status, and HER2 receptor status, using the categories specified above. We evaluated linear, nonlinear, and categorical specifications of the propensity score. The categorical specification, with propensity score classified in tertiles, was ultimately selected, although conclusions were not sensitive to the propensity score specification. The association of GEP on total charges was evaluated using propensity score-adjusted linear models, where the dependent variable was natural log-transformed total charges. Models were estimated in the full cohort and within subgroups stratified by clinically defined risk of recurrence. In a secondary analysis, among the subgroup of women who received an OncotypeDX test and had a documented result (n = 125), we examined the association of the OncotypeDX recurrence score on use of adjuvant chemotherapy, controlling for clinically defined risk of recurrence. All analyses were performed using Stata version 10 (StataCorp, College Station, TX). The study was reviewed and approved by the institutional review boards of UCSF, Partners Healthcare, and the New England Institutional Review Board.
Results
Sample characteristics
The majority of women in the sample were between the ages of 50 and 64 years, had no comorbidity, had cancers that were stage I or II, both estrogen and progesteronereceptor positive, and HER2-negative or intermediate (Table 1) . Based on clinical risk factors, 11.2% of women were categorized as having a low risk of recurrence, 38.2% had moderate risk, and 47.4% high risk. Women without comorbidity, and those with well-differentiated histology, HER2-negative or intermediate status, stage I disease, or tumor B3 cm in size were more likely than their respective counterparts to receive a GEP test. Use of GEP testing was highest among women with a moderate clinical risk of recurrence (52.0%) and lowest among those at high risk of recurrence (5.5%; P \ 0.001 across groups). Use of GEP 
Serious chemotherapy-associated adverse effects
Eleven percent of women had a hospital admission or emergency room visit with a diagnostic code suggestive of a serious chemotherapy-associated adverse effect (Table 3) . Not surprisingly, as the clinical risk of recurrence and the probability of receiving chemotherapy increased, so too did the likelihood of experiencing a chemotherapy-related serious adverse effect. However, GEP use was not associated with the occurrence of a chemotherapy-associated adverse effect either for the entire cohort or for the sub-groups of women defined by clinical risk of recurrence.
Charges following diagnosis
Median total charges for medical care in the first 12 months after diagnosis were $88,687 for all women in the sample (Table 4) . After adjusting for the propensity to receive a GEP test, there was no significant difference in total charges between those who did and did not receive GEP in the full sample (P = 0.91) or in the sub-groups of women defined by clinical risk of recurrence.
Discussion
In this payer-based sample, we found that GEP testing was associated with less use of adjuvant chemotherapy. In analyses stratified by risk groups using traditional clinical prognostic criteria, GEP testing was associated with less chemotherapy use among women at high clinical risk of recurrence, but was associated with more chemotherapy use among women with low clinical risk of recurrence. These results suggest that GEP testing influences both the overall rate of chemotherapy use and the type of patients who receive chemotherapy. Among the subgroup of women who received a GEP test, more women had their risk re-classified as lower than their clinical risk. GEP may result in more personalized care by providing additional reassurance to women at low clinical risk of recurrence who could forgo adjuvant chemotherapy, and identifying women who are at high recurrence risk who may benefit from more aggressive treatment [7, 9] . We did not see any association between GEP use and the occurrence of serious chemotherapy adverse-effects or charges during the 12 months following diagnosis. Together, these findings suggest that use of GEP may result in more ''personalization'' of chemotherapy use, but may not be associated with reduced serious chemotherapy-associated adverse events or cost savings, at least in the short term.
Prior studies provide limited evidence regarding the relationship between GEP testing and use of chemotherapy in routine practice settings. In one study of 269 women with non-metastatic breast cancer seen at a single cancer center, adjuvant chemotherapy was given to 7% of women with low recurrence score, compared to 42 and 86% of women with intermediate and high recurrence score, respectively [19] . In a different study of women with OncotypeDX testing, an independent oncologist was asked to review each chart and make a recommendation about the need for adjuvant chemotherapy without access to this test result [20] . OncotypeDX altered chemotherapy management for 38% of women for whom this independent assessment differed from that of the treating oncologist. In a third study, receipt of a GEP test was associated with a change in treatment recommendation, typically resulting in less use of chemotherapy, for one-third of patients, consistent with our findings [31] . None of these prior studies examined the relationship between GEP use and serious chemotherapy-associated adverse events. We found that while GEP use was associated with less chemotherapy use, and changes in patterns of use within subgroups of women defined by conventional clinical characteristics, this did not appear to translate into fewer serious adverse events.
Several economic simulations, with a longer time horizon than our study, suggest that GEP-guided therapy is associated with modest cost-saving compared with treatment decisions based on traditional clinical risk factors [7, [13] [14] [15] [16] [17] [18] . Our analysis, based on actual charges for care over a 12-month period, did not suggest a difference in costs associated with GEP test use. Based on the degree of precision of our estimates for GEP-related changes in total charges (Table 4) , our sample size was sufficient to detect a relative savings as small as 16%; smaller differences may be meaningful from a societal perspective. The lack of association between GEP testing and charges may perhaps reflect that a decrease in the use of chemotherapy for some patients was in part offset by an increase in use for others.
The premise that a genomic test could facilitate more individually tailored decision-making about the use of adjuvant chemotherapy is appealing from the perspective of women, their providers, and health care systems. Ultimate assessment of the value of these tests will depend on the availability of data regarding long-term outcomes of treatment decisions and the ability to track changes in utilization and outcomes over time. Data from ongoing randomized controlled trials to test the impact of GEP testing on outcomes will be critical to the assessment of the value of these tests [32] .
Our study has several limitations. As our findings are based on observational data, we cannot conclude that GEP Reference in adjusted analyses is women who did not receive a GEP test. Propensity score methods were used to control for confounding by characteristics that may be associated with receipt of a GEP test. Each woman's propensity to receive a GEP test was estimated as a function of her age at diagnosis, comorbidity score, year of diagnosis, tumor size, grade, nodal status, estrogen and progesterone receptor status, and HER2 receptor status, and was categorized in tertiles in adjusted model (11.9) testing was the cause of the observed differences in the use of chemotherapy. We used propensity score adjustment to address the potential selection bias that is inherent in observational data [33] . As noted above, we did not have data on long-term outcomes, which may be particularly important for women with non-metastatic disease. Finally, all women in our study were under age 65 and received coverage from a single, large health insurer. Thus, our findings may be less generalizable to the uninsured, older breast cancer patients covered by Medicare, or to women with Medicaid. The distribution of age, stage, and nodal status in our sample was similar to those observed for women with breast cancer in the Breast Cancer Surveillance Consortium [34] . Our sample does, however, include women who receive care across the US in diverse practice settings, including community-based practices. In this study of breast cancer patients treated in routine practice settings, GEP testing was associated with an overall decline in the use of adjuvant chemotherapy. While GEP testing is being used to tailor decision-making about the use of adjuvant chemotherapy, we did not demonstrate differences in serious chemotherapy-associated adverse events or charges during the 12 months following diagnosis.
